These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16822896)

  • 21. Summaries for patients. Neuropsychological side effects of efavirenz.
    Ann Intern Med; 2005 Nov; 143(10):I43. PubMed ID: 16287787
    [No Abstract]   [Full Text] [Related]  

  • 22. [Protease inhibitor saving alternatives].
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():16-7. PubMed ID: 10863305
    [No Abstract]   [Full Text] [Related]  

  • 23. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
    van Leth F; Lange JM
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efavirenz: practicalities, considerations and new issues.
    Moyle G
    Int J Clin Pract Suppl; 1999 Jun; 103():30-4. PubMed ID: 10622041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher efavirenz plasma levels correlate with development of insomnia.
    Núñez M; González de Requena D; Gallego L; Jiménez-Nácher I; González-Lahoz J; Soriano V
    J Acquir Immune Defic Syndr; 2001 Dec; 28(4):399-400. PubMed ID: 11707679
    [No Abstract]   [Full Text] [Related]  

  • 26. The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism.
    Alonso-Villaverde C; Coll B; Gómez F; Parra S; Camps J; Joven J; Masana L
    AIDS; 2005 Feb; 19(3):341-2. PubMed ID: 15718846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():39. PubMed ID: 11373776
    [No Abstract]   [Full Text] [Related]  

  • 28. Efavirenz-associated gynecomastia: report of five cases and review of the literature.
    Jover F; Cuadrado JM; Roig P; Rodríguez M; Andreu L; Merino J
    Breast J; 2004; 10(3):244-6. PubMed ID: 15125753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-nucleoside reverse transcriptase inhibitors--an overview.
    Bell C; Matthews GV; Nelson MR
    Int J STD AIDS; 2003 Feb; 14(2):71-7. PubMed ID: 12662384
    [No Abstract]   [Full Text] [Related]  

  • 30. Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash.
    Manosuthi W; Thongyen S; Chumpathat N; Muangchana K; Sungkanuparph S
    HIV Med; 2006 Sep; 7(6):378-82. PubMed ID: 16903982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reply. Lest we forget: neuropsychiatry and the new generation anti-HIV drugs.
    Gonzalez A; Everall I
    AIDS; 1999 Oct; 13(14):1996. PubMed ID: 10513671
    [No Abstract]   [Full Text] [Related]  

  • 32. [Didanosine--stability as backbone drug].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():83-4. PubMed ID: 16385888
    [No Abstract]   [Full Text] [Related]  

  • 33. Reply to Gonzalez and Everall: Lest we forget: neuropsychiatry and the new generation anti-HIV drugs.
    Colebunders R; Verdonck K
    AIDS; 1999 May; 13(7):869. PubMed ID: 10357394
    [No Abstract]   [Full Text] [Related]  

  • 34. [Efavirenz--comprehensive status of studies].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():79-81. PubMed ID: 16385886
    [No Abstract]   [Full Text] [Related]  

  • 35. New expanded access drugs for use in combination therapy.
    Notes Undergr; 1998; (No 37):suppl 1-2. PubMed ID: 11365823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.
    Funk MB; Notheis G; Schuster T; Elanjkal Z; von Hentig N; Stürmer M; Linde R; Dunsch D; Königs C; Wintergerst U; Kreuz W
    Eur J Med Res; 2005 Dec; 10(12):503-8. PubMed ID: 16356864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efavirenz effects worse than reported, study says.
    AIDS Alert; 2003 Jan; 18(1):9-10. PubMed ID: 12541997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [3 years' data of tenofovir. Confirmed as a valuable building block].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():30-1. PubMed ID: 15373042
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparing liver toxicity between efavirenz and nevirapine.
    TreatmentUpdate; 2002 Feb; 14(2):7-8. PubMed ID: 12691044
    [No Abstract]   [Full Text] [Related]  

  • 40. Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
    Prescrire Int; 2009 Jun; 18(101):105. PubMed ID: 19637416
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.